Comparative Pharmacology
Head-to-head clinical analysis: MERCAPTOPURINE versus XELODA.
Head-to-head clinical analysis: MERCAPTOPURINE versus XELODA.
MERCAPTOPURINE vs XELODA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mercaptopurine is a prodrug that is converted to 6-thioguanine nucleotides, which inhibit de novo purine synthesis and DNA replication by incorporating into DNA and RNA. It also inhibits purine nucleotide interconversions via feedback inhibition of amidophosphoribosyltransferase.
Prodrug of 5-fluorouracil (5-FU), inhibits thymidylate synthase, incorporates into RNA and DNA, leading to cell death.
1.5 to 2.5 mg/kg orally once daily; maintenance 1.5 to 2.5 mg/kg orally once daily.
Capecitabine 1250 mg/m2 orally twice daily for 2 weeks followed by a 1-week rest period, administered as 3-week cycles.
None Documented
None Documented
Terminal elimination half-life: 1.5-3 hours (variable); for active metabolites (e.g., 6-thioguanine nucleotides) half-life is 5-7 days, which correlates with myelosuppression.
Clinical Note
moderateMercaptopurine + Digoxin
"Mercaptopurine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMercaptopurine + Digitoxin
"Mercaptopurine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMercaptopurine + Deslanoside
"Mercaptopurine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMercaptopurine + Acetyldigitoxin
"Mercaptopurine may decrease the cardiotoxic activities of Acetyldigitoxin."
Capecitabine: 0.65-0.85 h; 5'-DFCR: 0.9-1.1 h; 5'-DFUR: 0.75-1.0 h; 5-FU: 0.75-1.1 h. Terminal half-life of 5-FU is short, requiring continuous dosing for sustained exposure.
Renal: 20-30% as unchanged drug; biliary/fecal: minor; extensive hepatic metabolism to active and inactive metabolites.
Renal (95.5% as metabolites; 26.1% as parent drug and metabolites, primarily 5'-DFCR, 5'-DFUR, and FBAL); fecal (< 3%)
Category D/X
Category C
Antimetabolite
Antimetabolite